Table 1.
Summary of baseline characteristics of patients with isolated CRC‐LM enrolled in the CAIRO5 trial and patients with isolated CRC‐PM enrolled in the CRC‐PIPAC trial.
| Characteristic | CRC‐LM cohort (N = 100) | CRC‐PM cohort (N = 20) |
|---|---|---|
| Age at inclusion (years, mean ± SD) | 60 ± 10 | 63 ± 9.8 |
| Sex (N [%]) | ||
| Male | 64 (64) | 12 (60) |
| Female | 36 (36) | 8 (40) |
| Primary tumor (N [%]) | ||
| Resected | 45 (45) | 6 (30) |
| Unresected | 55 (55) | 14 (70) |
| Metastases (N [%]) | ||
| Synchronous | 82 (82) | 15 (75) |
| Metachronous | 18 (18) | 5 (25) |
| Source of tumor tissue mutation analysis (N [%]) | ||
| Primary tumor | 91 (91) | 5 (25) |
| Metastases | 9 (9) | 2 (10) |
| Both | 0 (0) | 13 (65) |
| Tumor tissue mutation (N [%]) | ||
| KRAS | 54 (54) | 9 (45) |
| BRAF | 3 (3) | 2 (10) |
| No mutation detected | 43 (43) | 9 (45) |
| Systemic therapy <6 months before study registration (N [%]) | ||
| Yes | 0 (0) | 11 (55) |
| No | 100 (100) | 9 (45) |